ATE330595T1 - Formulierung von aminosäuren und riboflavin zur verringerung der toxischen effekte der zytotoxischen chemotherapie - Google Patents

Formulierung von aminosäuren und riboflavin zur verringerung der toxischen effekte der zytotoxischen chemotherapie

Info

Publication number
ATE330595T1
ATE330595T1 AT02789801T AT02789801T ATE330595T1 AT E330595 T1 ATE330595 T1 AT E330595T1 AT 02789801 T AT02789801 T AT 02789801T AT 02789801 T AT02789801 T AT 02789801T AT E330595 T1 ATE330595 T1 AT E330595T1
Authority
AT
Austria
Prior art keywords
amino acids
riboflaven
formulation
reduce
pharmaceutical compositions
Prior art date
Application number
AT02789801T
Other languages
English (en)
Inventor
Stanislaw R Burzynski
Original Assignee
Stanislaw R Burzynski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stanislaw R Burzynski filed Critical Stanislaw R Burzynski
Application granted granted Critical
Publication of ATE330595T1 publication Critical patent/ATE330595T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02789801T 2001-11-27 2002-11-21 Formulierung von aminosäuren und riboflavin zur verringerung der toxischen effekte der zytotoxischen chemotherapie ATE330595T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/995,010 US20030105104A1 (en) 2001-11-27 2001-11-27 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy

Publications (1)

Publication Number Publication Date
ATE330595T1 true ATE330595T1 (de) 2006-07-15

Family

ID=25541300

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02789801T ATE330595T1 (de) 2001-11-27 2002-11-21 Formulierung von aminosäuren und riboflavin zur verringerung der toxischen effekte der zytotoxischen chemotherapie

Country Status (21)

Country Link
US (2) US20030105104A1 (de)
EP (1) EP1450781B1 (de)
JP (1) JP4614660B2 (de)
KR (1) KR100953483B1 (de)
CN (1) CN100358527C (de)
AT (1) ATE330595T1 (de)
BR (1) BR0214430A (de)
CA (1) CA2468133C (de)
DE (1) DE60212693T2 (de)
EA (1) EA009516B1 (de)
HU (1) HU230986B1 (de)
IL (2) IL162141A0 (de)
MX (1) MXPA04004994A (de)
NO (1) NO332858B1 (de)
NZ (1) NZ532833A (de)
PL (1) PL353656A1 (de)
RO (1) RO121173B1 (de)
SI (1) SI21542A (de)
UA (1) UA78977C2 (de)
WO (1) WO2003045372A1 (de)
ZA (1) ZA200404115B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060293335A1 (en) * 2002-08-02 2006-12-28 Qishou Xu Riboflavin derivative and its manufacture and uses
US20060035981A1 (en) * 2003-08-02 2006-02-16 Mazzio Elizabeth A Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment
US20070248693A1 (en) * 2003-08-02 2007-10-25 Elizabeth Mazzio Nutraceutical composition and method of use for treatment / prevention of cancer
RU2240788C1 (ru) * 2003-09-09 2004-11-27 Воронежская государственная медицинская академия им. Н.Н. Бурденко Детоксикационное средство
ES2448549T3 (es) 2004-11-26 2014-03-14 Ucl Business Plc Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para tratar encefalopatía hepática
EP2328007B1 (de) * 2005-09-19 2014-12-24 CDM Optics, Inc. Aufgabenbasiertes bildgebungssystem
EP2826481A1 (de) 2006-03-15 2015-01-21 Suntory Holdings Limited Zusammensetzungen, die Riboflavin und Sesaminklassenverbindungen enthält
US20080249001A1 (en) * 2006-10-25 2008-10-09 Ajinomoto Co. Inc. Agents that alleviate side-effects caused by chemotherapy agents
WO2008105384A1 (ja) * 2007-02-26 2008-09-04 Kyowa Hakko Bio Co., Ltd. シトルリン含有錠剤
EP3342409A1 (de) 2007-03-15 2018-07-04 Suntory Holdings Limited Mittel gegen müdigkeit
US9101537B2 (en) 2008-07-25 2015-08-11 Reven Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
AU2014200578B2 (en) * 2008-09-19 2016-08-11 Société des Produits Nestlé S.A. Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment
CN102164595A (zh) 2008-09-19 2011-08-24 雀巢产品技术援助有限公司 抗癌治疗中的免疫系统营养支持
ES2652187T3 (es) 2009-04-03 2018-01-31 Ocera Therapeutics, Inc. Fenilacetato de l-ornitina y métodos para elaborar el mismo
EP2440200B8 (de) 2009-06-08 2014-10-15 UCL Business PLC Behandlung von pfortaderhochdruck mittels l-ornithin-phenylacetat
US8449512B2 (en) 2010-04-09 2013-05-28 Davinci Biomedical Research Products Inc. Stoma stabilitating device and method
EP2397458A1 (de) * 2010-06-21 2011-12-21 Lunamed AG Organische Salze und Co-Kristalle von Phenylbuttersäure
JP2013532661A (ja) 2010-07-22 2013-08-19 リベン ファーマシューティカルズ インコーポレイテッド 磁気双極子安定化溶液の使用を含む疾患を処置または改善する方法および行動を向上させる方法
EA030970B8 (ru) * 2010-09-24 2019-01-31 Юниверсити Оф Флорида Рисёч Фаундейшн, Инк. Композиция для восстановления функции тонкого кишечника, способы ее приготовления и применения
EP2625162B1 (de) 2010-10-06 2019-03-13 Ocera Therapeutics, Inc. Verfahren zur herstellung von l-ornithin-phenyl-acetat
WO2012079058A2 (en) 2010-12-10 2012-06-14 Broady Health Sciences, Llc Use of jasmonate to treat bladder dysfunction
JP6090836B2 (ja) * 2011-02-17 2017-03-08 Ｅａファーマ株式会社 化学療法剤の抗腫瘍活性増強剤
CA2839727C (en) * 2011-07-07 2023-10-17 Research Cancer Institute Of America Systems, methods, and formulations for treating cancer
EP4417256A3 (de) 2013-03-11 2024-10-23 University of Florida Research Foundation, Inc. Materialien und verfahren zur verbesserung der lungenfunktion
PL3065751T3 (pl) * 2013-11-08 2020-07-13 Legacy Healthcare Ltd Sposób leczenia raka i chorób współistniejących
JP6598425B2 (ja) * 2014-02-27 2019-10-30 花王株式会社 疲労の評価方法
KR102487376B1 (ko) 2014-11-24 2023-01-10 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
JP6990170B2 (ja) 2015-08-18 2022-01-12 オセラ セラピューティクス， インコーポレイテッド Ｌ－オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる筋肉喪失の治療および予防
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
CN105495582A (zh) * 2015-12-11 2016-04-20 北京康比特体育科技股份有限公司 一款抗疲劳、促恢复的保健食品氨基酸组合物
CN110740988A (zh) 2017-05-11 2020-01-31 欧塞拉治疗有限公司 制备l-鸟氨酸苯乙酸盐的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535049A (en) * 1978-09-04 1980-03-11 Otsuka Pharmaceut Factory Inc Amino acid transfusion for cancerous patient
JPS58126767A (ja) * 1982-01-22 1983-07-28 Ajinomoto Co Inc 肝臓病患者用栄養組成物
DE3672950D1 (de) * 1985-10-23 1990-08-30 Mulli Kurt Nachf Gmbh Thymusextraktfraktionen enthaltende pharmazeutische zusammensetzung.
US5045468A (en) * 1986-12-12 1991-09-03 Cell Enterprises, Inc. Protein-free culture medium which promotes hybridoma growth
ATE113441T1 (de) * 1989-10-02 1994-11-15 Sandoz Nutrition Ltd Proteinhydrolysaten.
US5292773A (en) * 1990-02-14 1994-03-08 Hirsch Gerald P Treating aids and HIV infection with methionine
CA2143420C (en) * 1992-12-23 1999-01-19 Phyllis J. B. Acosta Medical foods for the nutritional support of infant/toddler metabolic diseases
US5571783A (en) * 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
FR2705765B1 (fr) * 1993-04-29 1995-08-18 Eurofours Sa Porte de four.
NZ248605A (en) * 1993-05-28 1994-12-22 Abbott Lab Enteral nutritional product comprising protein and fat
US5547927A (en) * 1993-05-28 1996-08-20 Abbott Laboratories Enteral nutritional product for patients undergoing radiation therapy and/or chemotherapy
US5719133A (en) * 1994-09-21 1998-02-17 Novartis Nutrition Ag Adolescent dietary composition
US5656608B1 (en) * 1995-02-23 2000-09-26 Novartis Nutrition Ltd Amino acid compositions and methods of treatment using same
US5728678A (en) * 1995-06-06 1998-03-17 Nestec Ltd. Method and composition for providing nutrition to a renal failure patient
US5776913A (en) * 1995-10-10 1998-07-07 Colgate Palmolive Company Therapeutic diet for metabolic abnormalities found in animals with lymphoma
WO1997042939A1 (en) * 1996-05-14 1997-11-20 Burzynski Research Inst Liposomal antineoplaston therapies with markedly improved antineoplastic activity
US5817927A (en) * 1997-04-11 1998-10-06 Betzdearborn Inc. Method and apparatus for monitoring water process equipment
US5817695A (en) * 1997-12-24 1998-10-06 Pellico; Michael A. Nutritional product with high fat, low carbohydrate and amino acid imbalance
DE69910746T2 (de) 1999-06-26 2004-06-17 B. Braun Melsungen Ag Wässrige Lösung für parenterale Nahrung
GB0009056D0 (en) * 2000-04-12 2000-05-31 Nestle Sa Composition comprising free amino acids
US6377094B1 (en) * 2002-03-25 2002-04-23 Oak Technology, Inc. Arbitrary waveform synthesizer using a free-running ring oscillator

Also Published As

Publication number Publication date
ZA200404115B (en) 2005-11-30
PL353656A1 (en) 2003-06-02
EP1450781B1 (de) 2006-06-21
CN100358527C (zh) 2008-01-02
KR20040065565A (ko) 2004-07-22
EA200400737A1 (ru) 2004-12-30
EA009516B1 (ru) 2008-02-28
IL162141A (en) 2009-05-04
NO332858B1 (no) 2013-01-21
RO121173B1 (ro) 2007-01-30
US20050182064A1 (en) 2005-08-18
NZ532833A (en) 2006-12-22
US20030105104A1 (en) 2003-06-05
KR100953483B1 (ko) 2010-04-16
HUP0402240A3 (en) 2012-09-28
BR0214430A (pt) 2004-11-03
HUP0402240A2 (hu) 2005-02-28
UA78977C2 (en) 2007-05-10
MXPA04004994A (es) 2005-04-08
WO2003045372A1 (en) 2003-06-05
NO20042364L (no) 2004-06-07
AU2002352843A1 (en) 2003-06-10
DE60212693T2 (de) 2007-07-05
CA2468133C (en) 2011-02-22
JP4614660B2 (ja) 2011-01-19
CN1596109A (zh) 2005-03-16
DE60212693D1 (de) 2006-08-03
EP1450781A1 (de) 2004-09-01
SI21542A (sl) 2005-02-28
US7427619B2 (en) 2008-09-23
JP2005518361A (ja) 2005-06-23
IL162141A0 (en) 2005-11-20
HU230986B1 (hu) 2019-08-28
CA2468133A1 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
DE60212693D1 (de) Formulierung von aminosäuren und riboflavin zur verringerung der toxischen effekte der zytotoxischen chemotherapie
PT1416935E (pt) Derivados de 4-amino-6-fenil-pirrolo[2,3-d]pirimidina
EA200600877A1 (ru) Наночастицы для доставки лекарств
BR0305628A (pt) Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso
DE60228857D1 (de) Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung
NO991836D0 (no) Antranilinsyrederivater som modulatorer av multimedikamentresistens
MXPA02012164A (es) Derivados de tiofeno activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden.
AU2003218989A1 (en) Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
NO911854D0 (no) Fremgangsmaate for fremstilling av peptid-derivater.
MXPA04000920A (es) Derivados de aminoisoxazol activos como inhibidores de la cinasa.
TNSN05180A1 (en) Liquid pharmaceutical formulations of palonosetron
GEP20053510B (en) Substituted Pyrrolopyridinone Derivatives Useful as Phosphodiesterase Inhibitors
SE0102036D0 (sv) Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
YU64602A (sh) Smeša koja se sastoji od kamptotecina i derivata pirimidina za terapiju kancera
MXPA03010054A (es) Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.
ATE521624T1 (de) Peptide und medizinische zusammensetzungen mit denselben
WO2003068157A3 (en) Kinase inhibitors and methods of use thereof
ATE349221T1 (de) Extrakt mit antitumoraler und antitoxischer wirkung
NO20031410L (no) Anvendelse av distamycinderivater for fremstilling av medikamenter
FR12C0064I2 (fr) Compositions pharmaceutiques injectables d'un derive d'anthracenedione avec action anti-tumorale
EP1482933A4 (de) Wirkungsvolle vereinfachte derivate von immunosuppressiva
BRPI0507811A (pt) derivados de 7h-pirrolopirimidina
MX2023013301A (es) Una pluralidad de particulas tasquinimod y su uso.
MX2025011751A (es) Conjugados anticuerpo-farmaco de derivados de camptotecina y usos de estos

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties